Mesoblast is a world leader in developing innovative cellular medicines.
We have established what we believe is the industry's most clinically advanced and diverse portfolio of cell-based products with three programs in active Phase 3 clinical studies.
Our lead product candidates under investigation are:
- MPC-150-IM for chronic heart failure
- MPC-06-ID for chronic low back pain due to disc degeneration
- MSC-100-IV for acute graft versus host disease
- MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy
We also have a strong emerging pipeline of products for follow-on indications.
The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of late-stage product candidates.
These allogeneic, off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory conditions, spine orthopedic disorders, and oncology and hematology diseases.
Our licensee in Japan has launched its mesenchymal stem cell-based product, which is the first allogeneic cell-based product to receive full approval in Japan.
We believe we are well positioned to have the first industrially manufactured allogeneic stem cell product approved in the United States for the treatment of acute graft versus host disease (aGVHD) in children.
Mesoblast Corporate Backgrounder (2Mb)